Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United State…
$305.23-0.15%
报价 2026-11-13
市值
$9.05B
EV
$6.82B
PE (TTM)
35.3x
预期 PE (FY2026)
39.8x
52 周区间距高点 -19.3%
$204.10$378.15
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | $9.05B | -0.1% | +28.4% | 92.6% | 35.3x | 40.7x | 29.2x | |
| PCVXVaxcyte, Inc. | $10.03B | -2.0% | +4900.0% | 0% | – | – | – | |
| TGTXTG Therapeutics, Inc. | $9.75B | -0.1% | +61.4% | 83% | 15.5x | 50.3x | 560.9x | |
| PTGXProtagonist Therapeutics, Inc. | $8.55B | -2.6% | +1101.1% | 99.2% | – | – | 77.2x | |
| ALKSAlkermes plc | $7.9B | +0.1% | – | 86.6% | 55.6x | 35.6x | – | |
| ARWRArrowhead Pharmaceuticals, Inc. | $6.75B | +1.3% | -28.9% | 100% | – | – | – | |
| TFXTeleflex Incorporated | $6.15B | +1.3% | -31.3% | 53.3% | – | 63.6x | 15.9x | |
| PTCTPTC Therapeutics, Inc. | $5.3B | +0.2% | -28.6% | 92.4% | – | 33.3x | – | |
| CRSPCRISPR Therapeutics AG | $4.1B | -0.9% | – | -1,534.4% | – | – | – | |
| 同行中位数 | – | – | +16.4% | 84.8% | 35.5x | 43.0x | 77.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。